Table 2.
Continuous glucose monitoring use during the studya
| Overall (N = 34) |
Baseline HbA1c | |||||||
|---|---|---|---|---|---|---|---|---|
|
< 7.5%
(N = 11) |
7.5%-< 9.0%
(N = 11) |
≥ 9.0%
(N = 12) |
T1D
(N = 27) |
T2D
(N = 7) |
Pump
(n = 7) |
Injections
(N = 27) |
||
| Last 4 weeks of study | ||||||||
| Quantity of data available median (quartiles) | ||||||||
| % of possible data available | 96% (93%, 98%) |
96% (93%, 98%) |
97% (97%, 98%) |
94% (85%, 96%) |
97% (95%, 98%) |
93% (86%, 94%) |
97% (96%, 99%) |
96% (93%, 98%) |
| H of data available | 647 (623, 659) |
648 (623, 660) |
653 (649, 662) |
628 (574, 646) |
650 (635, 662) |
622 (579, 629) |
653 (647, 662) |
643 (622, 659) |
| D/wk of CGM use median (quartiles), n (%) | 7.0 (6.7, 7.0) | 7.0 (7.0, 7.0) | 7.0 (6.7, 7.0) | 6.7 (6.5, 7.0) | 7.0 (6.7, 7.0) | 6.7 (6.5, 7.0) | 7.0 (7.0, 7.0) | 7.0 (6.7, 7.0) |
| 7 d/wk | 29 (85%) | 10 (91%) | 10 (91%) | 9 (75%) | 25 (93%) | 4 (57%) | 7 (100%) | 22 (81%) |
| 6 d/wk | 3 (9%) | 1 (9%) | 1 (9%) | 1 (8%) | 0 (0%) | 3 (43%) | 0 (0%) | 3 (11%) |
| ≤ 5 d/wk | 2 (6%) | 0 (0%) | 0 (0%) | 2 (17%) | 2 (7%) | 0 (0%) | 0 (0%) | 2 (7%) |
| Entire study | ||||||||
| Quantity of data available median (quartiles) | ||||||||
| % of possible data available | 95% (93%, 97%) |
97% (95%, 98%) |
97% (93%, 98%) |
92% (89%, 94%) |
97% (94%, 98%) |
90% (89%, 96%) |
97% (95%, 98%) |
95% (90%, 97%) |
| H of data available | 1933 (1874, 1972) |
1957 (1928, 1972) |
1963 (1885, 1974) |
1853 (1790, 1912) |
1957 (1895, 1973) |
1818 (1798, 1943) |
1962 (1913, 1985) |
1928 (1818, 1972) |
| D/wk of CGM use median (quartiles), n (%) | 6.9 (6.7, 7.0) | 7.0 (6.9, 7.0) | 6.9 (6.7, 7.0) | 6.7 (6.3, 6.8) | 6.9 (6.7, 7.0) | 6.7 (6.2, 6.9) | 7.0 (6.9, 7.0) | 6.8 (6.7, 7.0) |
| 7 d/wk | 29 (85%) | 11 (100%) | 10 (91%) | 8 (67%) | 24 (89%) | 5 (71%) | 7 (100%) | 22 (81%) |
| 6 d/wk | 5 (15%) | 0 (0%) | 1 (9%) | 4 (33%) | 3 (11%) | 2 (29%) | 0 (0%) | 5 (19%) |
| ≤ 5 d/wk | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Abbreviations: CGM, continuous glucose monitoring; HbA1c, hemoglobin A1c; T1D, type 1 diabetes; T2D, type 2 diabetes.
aIn all analyses of CGM use, the warm-up period was ignored. This leads to a slight underestimate of use.